43 results about "Prostate cancer cell" patented technology

The invention relates to the technical field of biological medicine, and discloses an anti-human 5T4 single-chain antibody, the antibody has the capability of specifically binding to human 5T4 protein, the human 5T4 protein corresponds to TPBG / WAIF1, and the GenBank login number is NP001018111.1; the antibody also has the capability of specifically binding and expressing human 5T4 protein tumor cells, and the human 5T4 protein tumor cells are breast cancer cells MCF-7, prostate cancer cells PC3 or gastric cancer cells MGC-803. By combining single B cell culture with a magnetic bead sorting technology, natural pairing of a heavy chain and a light chain of an antibody can be reserved, and the defect that pairing is damaged by a traditional hybridoma technology is overcome; meanwhile, false positive clones are effectively eliminated through double positive screening of detecting protein binding activity through ELISA and detecting cell binding activity through FACS, the finally obtained targeting 5T4 monoclonal antibody can be specifically combined with human 5T4 protein and tumor cells expressing the protein, and a high-quality targeting molecular basis is provided for research and development of subsequent antibody drugs and CAR-T cell treatment products.

The invention discloses application of 6-methylcoumarin in preparation of a medicine for treating prostatic cancer, and relates to the technical field of medicines. The technical problem to be solved is to provide application of 6-methylcoumarin in preparation of drugs, health care products and functional food for treating prostatic cancer. The key point of the technical scheme is as follows: 6-methylcoumarin is used as an efficient ligand of an olfactory receptor OR51E2 to regulate prostate cancer cells so as to treat prostate cancer. In the prostate cancer cells LNCaP highly expressed by OR51E2, the 6-methylcoumarin can significantly inhibit cell proliferation, the inhibition effect of the 6-methylcoumarin is positively correlated with the action concentration of the 6-methylcoumarin, a new molecular target and a technical path are provided for prostate cancer treatment, the adopted 6-methylcoumarin has good chemical stability and application safety, and the 6-methylcoumarin has good application prospects. The potential of further drug development and transformation application is realized.

The application discloses application of UFSP2 as a target point in preparation of a prostate cancer treatment product. The application relates to the field of biological medicine, and research finds that UFM1 specific protease 2 (UFSP2) is highly expressed in prostate cancer tissues, and the protein level is higher than that of paracancerous tissues, and is positively correlated with the expression of proliferation related molecules c-Myc and CyclinD1. Function experiments further show that inhibition of UFSP2 expression can significantly inhibit the proliferation, clone formation and migration of prostate cancer cells, and inhibit the growth and metastasis of prostate cancer in vivo; on the contrary, overexpression of UFSP2 can promote the proliferation of prostate cancer cells, indicating that UFSP2 can be used as a prostate cancer treatment target and can be used for screening of anti-prostate cancer drugs. The application provides application of an UFSP2 expression inhibitor and / or a function inhibitor in preparation of a prostate cancer treatment product, and provides a new drug development direction and a targeted intervention strategy for prostate cancer treatment.

This invention relates to the field of biopharmaceutical technology, and in particular to the application of myrotoxin A in the preparation of drugs for treating prostate cancer. This invention is the first to discover the function of myrotoxin A in inducing ferroptosis in DU145 prostate cancer cells by targeting and inhibiting ACSL3 protein, and its inhibitory effect on prostate cancer proliferation. Specific embodiments of this invention reveal for the first time that myrotoxin A can precisely utilize the unique metabolic vulnerability of prostate cancer cells, significantly downregulating the expression of ACSL3 protein in DU145 cells at the protein level. This, in turn, by relieving the inhibition of ferroptosis by ACSL3 protein, specifically induces ferroptosis in prostate cancer cells, ultimately effectively inhibiting tumor cell growth and achieving the therapeutic goal of targeting prostate cancer development.

The application belongs to the technical field of biological medicine, and discloses application of a MYLK3 gene inhibitor in preparation of a drug for treating castration-resistant prostate cancer. The biological function of MYLK3 in prostate cancer is confirmed for the first time, an intervention means with the gene as a target point is provided, and it is confirmed that the MYLK3 inhibitor can improve the sensitivity of castration-resistant prostate cancer to androgen receptor antagonists. A gene therapy drug with the human MYLK3 gene as a treatment target point is specially provided, which is suitable for the treatment of prostate cancer (especially castration-resistant prostate cancer), and can also be combined with other targeted drugs to improve the treatment effect. By designing a reasonable RNAi target sequence for the target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, which has a significant inhibitory effect on the proliferation ability of prostate cancer cells, and significantly increases the sensitivity of prostate cancer cells to AR antagonists.

The invention relates to the technical field of biological medicine, and particularly discloses a bicyclic peptide for targeted degradation of FOXA1 protein and a preparation method and application thereof, and the amino acid sequence of the bicyclic peptide for targeted degradation of FOXA1 protein is as shown in SEQ ID NO.1. The bicyclic peptide capable of degrading the FOXA1 protein in the targeted manner, provided by the invention, can effectively degrade the FOXA1 protein, and shows the capability of remarkably inhibiting prostate cancer cell proliferation.

The present invention belongs to the technical field of biopharmaceuticals, and specifically relates to a tetrahydroquinoline NTD inhibitor and a use thereof. The present invention provides a novel NTD inhibitor, in which a bisphenol A moiety in EPI-002 is replaced with a tetrahydroquinoline structure, and rational drug design is carried out using this as a core scaffold, thereby enhancing the inhibitory activity of the compound against full-length AR and AR splice variants, while improving pharmacokinetic properties. The compound prepared in the present invention exhibits inhibitory effects toward the proliferation of castration-resistant prostate cancer cells and PSA luciferase activity, the effects thereof are superior to those of clinical drugs; it also possesses good oral bioavailability and plasma exposure.

The invention provides application of an AGGF1 expression inhibitor in preparation of a medicine for preventing and / or treating prostatic cancer. Through cell test and animal test analysis, it is determined that the preparation for inhibiting AGGF1 expression inhibits proliferation of prostate cancer cells by inhibiting expression of Wnt / beta-catenin pathway key protein beta-catenin and phosphorylation of GSK3B and / or by inhibiting oxidative stress, and therefore growth of tumors is effectively controlled.

The application discloses antisense oligonucleotides of METTL3 and application thereof in prostate cancer. It is found that inhibiting the expression level of METTL3 can reduce the proliferation of castration-resistant prostate cancer cells, and restore the drug sensitivity of drug-resistant prostate cancer cell strains, thereby providing a new means for treating castration-resistant prostate cancer and drug-resistant prostate cancer.

The present application relates to a kind of targeted degradation androgen receptor bifunctional chimeric heterocyclic compound and its purposes, specifically provides the compound shown in formula (I), or its isotopic compound, or its optical isomer, or its tautomer, or its pharmaceutically acceptable salt, or its prodrug, or its solvate, wherein, ARB is androgen receptor recognition / binding portion, L is linking portion, U is ubiquitin protease recognition / binding portion;Three parts are connected by chemical bond.The above-mentioned compound provided by the present application can target degradation androgen receptor in prostate cancer cell, and inhibit the proliferation of prostate cancer cell, also show good metabolic stability and pharmacokinetic property.The compound of the present application has good application prospect in the preparation of androgen receptor protein degradation targeting chimera, and the preparation of the drug for treating related diseases (including prostate cancer, breast cancer, Kennedy disease) regulated by androgen receptor.

The application discloses application of convallatoxin in preparation of a medicine for resisting prostate cancer and belongs to the technical field of biological medicines. The application finds that the convallatoxin has the efficacy of resisting prostate cancer, and the increase of UPP1 expression can enhance the inhibiting effect or the apoptosis induction effect of the convallatoxin on prostate cancer cells. Compared with the group of using the convallatoxin alone, after the 22Rv1 cells overexpressing UPP1 are treated by the convallatoxin, the apoptosis rate of the cells is increased by about 4 times, which indicates that the increase of UPP1 expression can enhance the effect of the convallatoxin on inducing the apoptosis of the prostate cancer cells.

The application belongs to the technical field of biological medicine, and particularly relates to a dipicolinate ester derivative and application thereof. The dipicolinate ester derivative has broad-spectrum antitumor activity, can significantly inhibit the proliferation activity of lung cancer cells, pancreatic cancer cells and prostate cancer cells, and has more excellent inhibitory activity on lung cancer cells, and can significantly inhibit the growth of mouse subcutaneous small cell lung cancer transplanted tumors. In addition, the dipicolinate ester derivative has no toxic effect on normal cells of the body, can be applied to preparation of anticancer drugs, and has broad application prospects in the aspect of anticancer.

The invention discloses an abiraterone borane carrying agent with prostatic cancer targeting property as well as a preparation method and application of the abiraterone borane carrying agent. The abiraterone borane compound comprises abiraterone borane and abiraterone acetate borane. According to the embodiment of the invention, based on abiraterone acetate and prostatic cancer targeting and safety of abiraterone, a borane group is introduced into structures of abiraterone acetate and abiraterone acetate, and a novel boron carrying agent is obtained and is used for BNCT treatment of prostatic cancer. The novel boron carrying agent not only retains the CYP17 enzyme inhibitory activity of abiraterone and abiraterone acetate, but also provides the possibility of targeting prostate cancer cells for BNCT by introducing a 10B isotope. Through the innovative medicine design, the curative effect and selectivity of BNCT in prostatic cancer treatment can be remarkably improved, damage to normal tissue is reduced, and a safer and more effective treatment choice is provided for prostatic cancer patients.

This invention discloses a class of androgen receptor modulators, their preparation methods, and applications. The androgen receptor modulators are selected from compounds having the structural formula shown in Formula I. Experimental verification has shown that these compounds are all androgen receptor modulators, capable of significantly reducing the expression levels of androgen receptors in various cells and effectively inhibiting the proliferation of prostate cancer cells. They exhibit good safety profiles and have potential for further development.

This invention relates to the field of biomedical technology, specifically disclosing a bicyclic peptide for targeted degradation of FOXA1 protein, its preparation method, and its applications. The amino acid sequence of the bicyclic peptide for targeted degradation of FOXA1 protein is shown in SEQ ID NO.1. The bicyclic peptide for targeted degradation of FOXA1 protein provided by this invention can effectively degrade FOXA1 protein and exhibits the ability to significantly inhibit the proliferation of prostate cancer cells.

To provide a consensus prostate antigen, a nucleic acid molecule encoding the same, a vaccine containing the same and use thereof.SOLUTION: Provided herein are consensus amino acid sequences of prostate antigens capable of breaking tolerance in a target species, including PSA, PSMA, STEAP, and PSCA antigens. Also provided are nucleic acid sequences encoding a consensus amino acid sequence of one or more of the prostate antigens PSA, PSMA, STEAP, and PSCA, as well as genetic constructs / vectors and vaccines expressing such sequences. Also provided herein are methods of generating an autoimmune response against prostate cancer cells by administering one or more of the provided vaccines, proteins, and / or nucleic acid sequences.SELECTED DRAWING: None

Described herein are compositions, pharmaceutical compositions, kits, and methods of use relating to anti-Dio3os antisense RNA. In embodiments, antisense Dio3os compositions, kits, and methods are described to improve symptoms of osteoporosis, for example, osteoporosis induced by a disorder characterized by a thyroid hormone imbalance (i.e., hyperthyroidism or hypothyroidism). In embodiments, antisense Dio3os compositions, kits, and methods are described to improve sensitivity of cancer cells to anti-cancer therapeutics, for example, sensitivity of ER+ breast cancer or other breast cancer cells, thyroid cancer cells, prostate cancer cells, hepatocellular cancer cells, pancreatic cancer cells, and ovarian cancer cells that are sensitized or otherwise non-responsive to cancer therapeutics (for example, aromatase inhibitors or HDAC inhibitors). Combination therapies are also contemplated utilizing antisense RNA according to the present disclosure and other drugs, for example, thyroid and anti-cancer medications.

The invention relates to the technical field of medicines, in particular to application of ginkgo terpene lactone in preparation of medicines for prevention, treatment and / or adjuvant treatment of prostatic cancer. The ginkgo terpene lactone and a composition or extract thereof can inhibit cell proliferation of prostatic cancer cell lines, have a quality effect on prostatic cancer, and can be used for preparing medicines for preventing, treating and / or adjunctively treating prostatic cancer. The compound can be used for preparing medicines for treating prostatic cancer.

This invention discloses an intracellular imaging system for simultaneously detecting UDG and miR-375 expression levels and its applications. The intracellular imaging system uses a tetrahedral DNA nanostructure as a carrier, loading a HAT-UDG probe with an on / off conformation, and coupling it with a split CRISPR / Cas12a detection component for recognizing miR-375. The split CRISPR / Cas12a detection component includes at least Cas12a protein, scaffold RNA, spacer RNA / equivalent split crRNA components, and a fluorescent reporter substrate. This invention is the first to perform a logical AND operation between two key indicators: UDG enzyme activity and miR-375 expression level. The system can only ultimately trigger a complete fluorescence signal when both are simultaneously highly expressed. This multi-target synergistic activation design constructs a precise molecular recognition logic gate, enabling extremely accurate differentiation between prostate cancer cells (RV-1) and normal cells (293T), as well as other cancer cells (5637) that highly express UDG, fundamentally avoiding misjudgments caused by fluctuations in a single indicator or non-specific expression, resulting in extremely high imaging specificity.

The application discloses a combined drug for treating prostate cancer and application, the combined drug is a combined drug of FEN1-IN-4 and TRi-1 administered respectively or simultaneously, the FEN1-IN-4 is an inhibitor targeting Flap endonuclease 1, and the TRi-1 is an inhibitor targeting thioredoxin (TXN) antioxidant system.The combined treatment scheme of FEN1-IN-4 and TRi-1 provided by the application firstly shows a strong antitumor effect superior to single drug in vitro experiment.FEN1-IN-4 as FEN1 specific inhibitor can block the endonuclease function of FEN1 by combining with the active site of FEN1, and can achieve significant growth inhibition to various prostate cancer cell lines such as LNCaP, 22RV-1, PC3, DU145, and the like, and TRi-1 as TXN antioxidant system inhibitor can target to destroy the oxidative stress balance of tumor cells, and the two act on different key pathways (DNA replication / damage repair pathway and antioxidant defense pathway) of tumor cells, forming a "double targeting" synergistic effect.

The present application relates to a kind of indole maleimide derivatives and its application, belong to heterocyclic compound synthesis technical field, solve the problem that the kind of drug for treating cancer is not enough rich at present.The indole maleimide derivative of the present application has the structure as shown in structure formula 4: And / or, with the structure as shown in structure formula 3.The indole maleimide derivative of the present application has obvious inhibitory effect on the proliferation of human leukemia cells (K562) and prostate cancer cells (PC-3).

The present disclosure describes a GnRH therapeutic for neutralizing GnRH levels in subjects which can reduce testosterone levels to attenuate or eliminate prostate cancer cell growth and / or metastasis. The therapeutic is produced synthetically. The GnRH therapeutic includes a hapten carrier (hC) comprising a monomeric peptide (MP), synthesized separately from the GnRH peptide, and following self-assembly of the hC, GnRH is covalently coupled to form a GnRH-hC conjugate which can serve as a therapeutic. The MP includes heptad repeats following a specific pattern. The hC can include a GnRH peptide attached to a monomeric peptide prior to self-assembly to form a therapeutic. Optionally, the GnRH-hC conjugate further includes one or more T-cell epitopes at the N- and / or C-terminus of the one or more amphipathic alpha-helices. The present disclosure also describes compositions including immunogenic compositions including the therapeutics described herein.

The invention belongs to the technical field of biological medicines, and discloses application of an MYLK3 gene inhibitor in preparation of a medicine for treating castration-resistant prostate cancer. The biological function of the MYLK3 in the prostatic cancer is confirmed for the first time, an intervention means taking the MYLK3 as a target spot is provided, and it is clear that the MYLK3 inhibitor can improve the sensitivity of the castration-resistant prostatic cancer to an androgen receptor antagonist. The invention particularly provides a gene therapeutic drug taking the human MYLK3 gene as a therapeutic target, which is suitable for treating prostatic cancer (especially castration-resistant prostatic cancer) and can also be used in combination with other targeted drugs to improve the therapeutic effect. A reasonable RNAi target sequence is designed for a target gene, a retrovirus vector plasmid containing the target sequence is successfully constructed, the retrovirus vector plasmid has a remarkable inhibition effect on the proliferation capacity of prostate cancer cells, and meanwhile, the sensitivity of the prostate cancer cells to AR antagonists is remarkably improved.

The application discloses a radionuclide diagnostic and therapeutic agent for targeting CDK19, and belongs to the technical field of biological medicines. Bone metastatic prostate cancer has a poor prognosis in men and is significantly associated with mortality. CDK19 is specifically highly expressed in prostate cancer cells, and a complex formed by CDK19 is involved in the occurrence and development of bone metastasis of prostate cancer, and is a new specific target for treatment and diagnosis of bone metastatic prostate cancer. The radionuclide conjugated drug for targeting CDK19 has a good application prospect in the fields of preparation of diagnostic, staging and therapeutic agents for prostate cancer and medicines.

The invention relates to bionic chitosan hybrid nanogel for treating prostatic cancer osseous metastasis and a preparation method and application thereof, the hybrid nanogel is prepared by the following steps: carrying out a cross-linking reaction on a chitosan monomer and a cross-linking agent glutaraldehyde, introducing ultra-small ferroferric oxide nanoparticles in the reaction process to form the hybrid nanogel, and then loading zoledronic acid to obtain the bionic chitosan hybrid nanogel for treating prostatic cancer osseous metastasis. And further coating a prostate cancer cell membrane. After entering a tumor-bearing nude mouse body through tail vein injection, the pH response type bionic hybrid nanogel prepared by the invention has the advantages of remarkable prostate cancer bone metastasis inhibition and excellent T1 magnetic resonance imaging performance, and has potential clinical application value.

The present application belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating prostate cancer and a preparation method thereof. The traditional Chinese medicine composition is prepared from raw materials including the following components by weight: cassia twig 5-50 parts, poria 5-50 parts, cortex moutan 3-30 parts, red peony root 3-30 parts, persicae semen 3-30 parts, fructus psoraleae 1-20 parts, and drynaria 1-20 parts. The present application proves through experiments that the traditional Chinese medicine composition can effectively inhibit the proliferation, migration and invasion of prostate cancer cells. Through extensive transcriptome analysis, it is found that the traditional Chinese medicine composition inhibits the expression of key genes such as HSP90AA1 and CDK1, and regulates the PI3K signal pathway and AR signal transduction in the prostate cancer pathway to achieve inhibition of prostate cancer. Therefore, the traditional Chinese medicine composition has a good application prospect.

The invention relates to a method for researching an action mechanism of organic framework nanoparticles on prostate cancer cells. The nanoparticles are PSMA-PEG-MOF (at) Enza + CpG, a pH responsive metal organic framework (MOF) carrier is synthesized through a solvothermal method, PEG and prostate specific membrane antigen (PSMA) antibody surface modification is sequentially performed, and then enzalutamide (Enza) and CpG oligodeoxynucleotide are co-loaded. According to the method disclosed by the invention, the killing effect of the nanoparticles on dendritic cell (DC) maturation, T cell activation and tumor cells is evaluated through an in-vitro experiment; the invention provides a set of complete research scheme for illustrating a specific molecular and cellular mechanism of the targeting nanoparticles for synergistically inhibiting tumor growth and activating anti-tumor immunity.